Skip to main content
TipRanks
Go Ultimate75% OFF

OptiBiotix Health (OB3) AI Stock Analysis

0 Followers
DE:OB3

OptiBiotix Health

(Frankfurt:OB3)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue GrowthThe sharpest recent revenue increase indicates stronger commercial traction for OptiBiotix’s probiotic and microbiome portfolio. If partner-led demand continues, greater product adoption can expand the licensing and ingredient opportunity while providing a broader base over which operating costs may be leveraged.
Negative Factors
Persistent LossesMaterial and widening losses show that current revenue is not yet sufficient to cover the company’s operating cost base. Unless commercial growth improves operating leverage, continued losses could constrain investment capacity and leave the business dependent on external funding to sustain development and market expansion.

OptiBiotix Health (OB3) vs. iShares MSCI Germany ETF (EWG)

-40%-30%-20%-10%0%10%20%DE:OB3-31.76%EWG+9.15%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 4.70M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-1.1
Beta (1Y)
0.84
Revenue Growth
8.23%
EPS Growth
-2881.25%
Country
Germany
Employees
9
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

OptiBiotix Health Business Overview & Revenue Model

Company Description

OptiBiotix Health Plc, a life sciences enterprise headquartered in York, United Kingdom, specializes in the discovery and advancement of microbiome-modulating technologies. The company formulates distinct microbial strains, innovative compounds, and...

OptiBiotix Health Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:OB3 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:SBTXGB:SBTX59NeutralGBP 12.31M-25.00-5.25%―95.16%85.60%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:TCFGB:TCF42NeutralGBP 4.64M-1.70-93.92%――55.56%
GB:CIZGB:CIZ39UnderperformGBP 5.52M-7.03192.61%――42.86%
GB:NFXGB:NFX39UnderperformGBP 2.48M-2.02-83.53%――93.02%
GB:FUMGB:FUM31UnderperformGBP 3.71M-0.44-152.41%―-70.77%60.39%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%DE:OB3GB:TCFGB:FUMGB:NFXGB:CIZGB:SBTXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:OB3 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:OB3OptiBiotix Health0.06-0.03-34.83%
GB:TCFEvgen Pharma0.17-0.04-19.05%
GB:FUMFutura Medical0.28-1.00-78.13%
GB:NFXNuformix Plc0.10-0.18-65.45%
GB:CIZCizzle Biotechnology Holdings PLC1.13-0.52-31.82%
GB:SBTXSkinBioTherapeutics plc4.50-11.00-70.97%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.